Blai Coll

CMO, Structure Therapeutics

Thousand Oaks, California

About

Male

Blai Coll is the CMO of Structure Therapeutics. He previously worked at Amgen as a Cardiovascular and Metabolic Platform Lead. Blai Coll attended Universitat Rovira i Virgili.

Experience

Structure Therapeutics

CMO

View →

IPO188South San Francisco, California, United StatesBiotech/Pharma · Biotechnology

Education

Universitat Rovira i Virgili · PhD, Medicine
2004 – 2007

Headlines from Google News. Social posts load from the platform only when you open a tab.

Structure Therapeutics at Cantor conference: oral obesity push advances By Investing.com
Investing.com Australia · Sep 11
Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial
nature.com · Jun 5
Structure Therapeutics reports more Phase 2 data for oral GLP-1
Endpoints News · Apr 7
GLP-1 Side Effects Only One Factor Driving Patient Discontinuation Rates
BioSpace · Mar 10
Evidence Mounts for Benefit of GLP-1s Against Heart Disease
BioSpace · Jan 6

People at Structure Therapeutics

Raymond Stevens

Chief Executive Officer & Founder

Data from: crunchbase